Solid Biosciences (SLDB) Operating Leases (2019 - 2026)

Solid Biosciences has disclosed Operating Leases across 8 years of filings, most recently posting $18.5 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $18.5 million, down 10.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.5 million (down 10.57% YoY), and the FY2025 annual result was $19.1 million, down 9.93% from the prior year.
• Operating Leases came in at $18.5 million for Q1 2026 at Solid Biosciences, down from $19.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $24.5 million in Q2 2022 to a low of $70000.0 in Q1 2022.
• The 5-year median for Operating Leases is $22.1 million (2024), against an average of $20.7 million.
• Across the five-year window, Operating Leases tumbled 96.46% in 2022 and surged 34060.0% in 2023, its largest moves.
• Solid Biosciences' Operating Leases stood at $24.3 million in 2022, then retreated by 6.47% to $22.7 million in 2023, then dropped by 6.82% to $21.2 million in 2024, then declined by 9.93% to $19.1 million in 2025, then dropped by 3.04% to $18.5 million in 2026.
• The last three Operating Leases figures came in at $18.5 million (Q1 2026), $19.1 million (Q4 2025), and $19.6 million (Q3 2025), per Business Quant data.